These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 17316873)

  • 1. Effect of hepatitis C virus treatment in fibrosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus: a paired liver biopsy study.
    Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; Marxuach-Cuétara AM; López-Torres A; Jiménez-Rivera J
    J Hepatol; 2007 Apr; 46(4):613-9. PubMed ID: 17316873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
    Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
    J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
    Hornberger J; Torriani FJ; Dieterich DT; Bräu N; Sulkowski MS; Torres MR; Green J; Patel K
    J Clin Virol; 2006 Aug; 36(4):283-91. PubMed ID: 16765638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of a maintenance therapy with peg-interferon alpha-2a on liver fibrosis in HIV/HCV co-infected patients: a randomized controlled trial.
    Chapplain JM; Bellissant E; Guyader D; Molina JM; Poizot-Martin I; Perré P; Pialoux G; Turlin B; Mouchel C; Renault A; Michelet C;
    J Infect; 2013 Oct; 67(4):313-21. PubMed ID: 23800784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis.
    Everson GT; Balart L; Lee SS; Reindollar RW; Shiffman ML; Minuk GY; Pockros PJ; Govindarajan S; Lentz E; Heathcote EJ
    Aliment Pharmacol Ther; 2008 Apr; 27(7):542-51. PubMed ID: 18208570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consensus guidelines for the management of hepatitis C infection.
    Consensus Guidelines Committee for the Management of Hepatitis C Infection
    Saudi Med J; 2003 Jul; 24 Suppl 2():S99-118. PubMed ID: 25121186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Peg-interferon alfa-2a and highly active antiretroviral drug therapy on hepatitis C patients with AIDS].
    Zhang RF; Sun HQ; Huang Q; Wang JR; Zhang XX; Liu XN; Lu HZ
    Zhonghua Gan Zang Bing Za Zhi; 2007 Oct; 15(10):734-7. PubMed ID: 17963597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C).
    Sherman KE; Andersen JW; Butt AA; Umbleja T; Alston B; Koziel MJ; Peters MG; Sulkowski M; Goodman ZD; Chung RT;
    J Acquir Immune Defic Syndr; 2010 Dec; 55(5):597-605. PubMed ID: 20921898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series.
    Mukherjee S; Lyden E
    Hepatogastroenterology; 2006; 53(70):561-5. PubMed ID: 16995462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus.
    Aguilar Marucco D; Veronese L; de Requena DG; Bonora S; Calcagno A; Cavecchia I; Sinicco A; De Rosa FG; Cariti G; Di Perri G
    J Antimicrob Chemother; 2007 Mar; 59(3):565-8. PubMed ID: 17213263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral therapy and fibrosis progression in patients with mild-moderate hepatitis C recurrence after liver transplantation. A randomized controlled study.
    Belli LS; Volpes R; Graziadei I; Fagiuoli S; Starkel P; Burra P; Alberti AB; Gridelli B; Vogel W; Pasulo L; De Martin E; Guido M; De Carlis L; Lerut J; Cillo U; Burroughs AK; Pinzello G
    Dig Liver Dis; 2012 Jul; 44(7):603-9. PubMed ID: 22424641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.
    Heathcote EJ; Shiffman ML; Cooksley WG; Dusheiko GM; Lee SS; Balart L; Reindollar R; Reddy RK; Wright TL; Lin A; Hoffman J; De Pamphilis J
    N Engl J Med; 2000 Dec; 343(23):1673-80. PubMed ID: 11106716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of hepatitis C in patients with haemophilia - the Israeli National Hemophilia Center experience.
    Maor Y; Schapiro JM; Bashari D; Lurie Y; Safadi R; Segol O; Paritsky M; Rachlis Z; Avidan B; Bar-Meir S; Martinowitz U
    Haemophilia; 2008 Mar; 14(2):336-42. PubMed ID: 18205802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
    Zimmermann T; Böcher WO; Biesterfeld S; Zimmermann A; Kanzler S; Greif-Higer G; Barreiros AP; Sprinzl MF; Wörns MA; Lohse AW; Mönch C; Otto G; Galle PR; Schuchmann M
    Transpl Int; 2007 Jul; 20(7):583-90. PubMed ID: 17433090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C.
    Ross AS; Bhan AK; Pascual M; Thiim M; Benedict Cosimi A; Chung RT
    Clin Transplant; 2004 Apr; 18(2):166-73. PubMed ID: 15016131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rate of cirrhosis progression reduced in HIV/HCV co-infected non-responders to anti-HCV therapy.
    De Bona A; Galli L; Gallotta G; Guzzo A; Alagna L; Lazzarin A; Uberti-Foppa C
    New Microbiol; 2007 Jul; 30(3):259-64. PubMed ID: 17802905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin resistance and HCV virologic response to peg-interferons (Peg-IFN) with ribavirin (RBV) in HIV/HCV co-infected patients.
    Donato C; Cingolani A; Pinnetti C; De Luca A
    J Hepatol; 2010 Feb; 52(2):306-7. PubMed ID: 20006404
    [No Abstract]   [Full Text] [Related]  

  • 19. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
    Napoli N; Giannelli G; Antonaci A; Antonaci S
    J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is time to treat for HCV all the HIV/HCV co-infected hemophiliacs?
    Franchini M
    Hematology; 2006 Jun; 11(3):209-13. PubMed ID: 17325964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.